What digital therapeutic treatment for opioid use disorder will soon be available to complement psychiatric care?
Robert DeLuca, RPh, president of Orexo US, talks about the new and upcoming digital therapeutic, modiaTM, and its aim to help close the gap in care for patients with opioid use disorder. You can learn more by visiting orexo.com or reaching out to firstname.lastname@example.org. Modia™ is expected to be available later this year.
Robert DeLuca, RPh, is President of Orexo US and has more than 25 years of industry experience at several multinational pharmaceutical companies. In addition to his demonstrated track record of success in the pharmaceutical industry with a combined background in global commercial operations, marketing, market access, and sales, DeLuca is also a New Jersey licensed pharmacist. He practiced retail pharmacy for 3 years post licensure prior to entering the corporate arena. DeLuca also is on the St. John’s College of Pharmacy Advisory Board and has memberships in the Academy of Managed Care Pharmacy (AMCP) and in the American Pharmacists Association.